BPMC   $94.18  -2.53% Market Closed After Close 94.15 -0.03%

Blueprint Medicines Corp
Last Events:

2023-08-09 Trend Power changed from slow to almost flat.

2023-08-06 Trend pattern changed from канал to расходящийся клин с наклоном вверх.

2023-08-05 Signal in MACD changed from bullish weakening to bearish. Oscillator MACD is in the negative territory it crossed the signal line from the top and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: main and signal line crossing.

2023-08-04 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-04 Signal in MACD changed from bullish to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: up-crossing the middle level.

2023-08-04 Signal in RSI changed from bullish weakening to bearish. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.

2023-08-04 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-04 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 19
Target Price Mean 125.58
Mean unverified/preliminary 125.58 / 125.58
Target Price Low / High 81.00 / 167.00
Median / STD DEV 130.00 / 22.81
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy ActivelyBuy
rsi Sell Buy None
macd None None None
stoch None None None
ma20 Buy None None
ma50 None None None
ma100 ActivelyBuy Buy ActivelyBuy
Candlestick PatternNov. 20, 2024 After Top Gap Down - pattern is a made up of five candlesticks. Pattern appears on a uptrend. The pattern begins with a white candlestick. The next two days are also white days. The third day gaps up and opens above the close of the second day. The fifth day is a strong black with a gap below the previous day’s close. Considered to be a bearish reversal pattern.
ISIN US09627Y1091
ceo Ms. Kathryn Haviland M.B.A.
Website https://www.blueprintmedicines.com
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.